(Total Views: 413)
Posted On: 12/09/2019 4:14:10 PM
Post# of 72446
Unbelievable numbers. By 2024 cancer drug revenues expected to increase to $250 Billion per year according to the article you posted.
If, or more likely WHEN, the Kevetrin pill shows anywhere near the promise most of us expect in either becoming a stand-alone treatment or a highly successful complementary drug for multiple cancer treatments, its value will be astronomical.
The numbers that have been bandied about, and mostly scoffed at, by many may turn out to be way low IMO.
Combine this potential with Brilacidin having the possibility to become as well known a medicine as Aspirin and IPIX has the potential to be a major player in the biotech arena.
Though we are paupers today, tomorrow we may be anything but.
The future is our friend IMO.
If, or more likely WHEN, the Kevetrin pill shows anywhere near the promise most of us expect in either becoming a stand-alone treatment or a highly successful complementary drug for multiple cancer treatments, its value will be astronomical.
The numbers that have been bandied about, and mostly scoffed at, by many may turn out to be way low IMO.
Combine this potential with Brilacidin having the possibility to become as well known a medicine as Aspirin and IPIX has the potential to be a major player in the biotech arena.
Though we are paupers today, tomorrow we may be anything but.
The future is our friend IMO.
(7)
(1)
